These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16488648)

  • 1. RANKL inhibitors: a bright future?
    Roux S
    Joint Bone Spine; 2006 Mar; 73(2):129-31. PubMed ID: 16488648
    [No Abstract]   [Full Text] [Related]  

  • 2. RANK, RANKL and osteoprotegerin in arthritic bone loss.
    Bezerra MC; Carvalho JF; Prokopowitsch AS; Pereira RM
    Braz J Med Biol Res; 2005 Feb; 38(2):161-70. PubMed ID: 15785827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting the seed and soil theory of bone metastasis: new tools, same answer.
    Kostenuik PJ
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):375-6. PubMed ID: 15758267
    [No Abstract]   [Full Text] [Related]  

  • 4. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T; Nakashima T; Hiroshi N; Penninger JM
    Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
    Roux S; Mariette X
    Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of RANKL might reduce bone metastases .
    Burton A
    Lancet Oncol; 2006 May; 7(5):367. PubMed ID: 16696160
    [No Abstract]   [Full Text] [Related]  

  • 8. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders.
    Juji T; Hertz M; Aoki K; Horie D; Ohya K; Gautam A; Mouritsen S; Oda H; Nakamura K; Tanaka S
    J Bone Miner Metab; 2002; 20(5):266-8. PubMed ID: 12203031
    [No Abstract]   [Full Text] [Related]  

  • 9. The mechanisms of estrogen regulation of bone resorption.
    Riggs BL
    J Clin Invest; 2000 Nov; 106(10):1203-4. PubMed ID: 11086020
    [No Abstract]   [Full Text] [Related]  

  • 10. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
    Wittrant Y; Theoleyre S; Couillaud S; Dunstan C; Heymann D; Rédini F
    Exp Cell Res; 2004 Feb; 293(2):292-301. PubMed ID: 14729467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance.
    Lubberts E; van den Bersselaar L; Oppers-Walgreen B; Schwarzenberger P; Coenen-de Roo CJ; Kolls JK; Joosten LA; van den Berg WB
    J Immunol; 2003 Mar; 170(5):2655-62. PubMed ID: 12594294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].
    Stajszczyk M
    Pol Arch Med Wewn; 2002 Sep; 108(3):915-24. PubMed ID: 12600190
    [No Abstract]   [Full Text] [Related]  

  • 13. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S; Nakamura K; Takahasi N; Suda T
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
    Hofbauer LC; Heufelder AE
    J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
    Hofbauer LC
    Ann Endocrinol (Paris); 2006 Apr; 67(2):139-41. PubMed ID: 16639364
    [No Abstract]   [Full Text] [Related]  

  • 17. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis.
    Hofbauer LC; Heufelder AE
    Eur J Endocrinol; 1998 Aug; 139(2):152-4. PubMed ID: 9724069
    [No Abstract]   [Full Text] [Related]  

  • 18. RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation.
    Ashcroft AJ; Carding SR
    Gut; 2005 Sep; 54(9):1345-6. PubMed ID: 16099805
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone lysis and inflammation.
    Haynes DR
    Inflamm Res; 2004 Nov; 53(11):596-600. PubMed ID: 15693607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands.
    Horowitz MC; Xi Y; Wilson K; Kacena MA
    Cytokine Growth Factor Rev; 2001 Mar; 12(1):9-18. PubMed ID: 11312114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.